Abstract: Provided are an anti-CLDN-18.2 antibody-drug conjugate that specifically binds to CLDN-18.2 and a composition comprising same. Also provided are a method for using the antibody-drug conjugate of the present invention and a use thereof.

Abstract: The present invention belongs to the field of biopharmaceuticals and relates to an anti-DKK1 antibody, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention relates to an anti-DKK1 antibody or an antigen-binding fragment thereof, wherein the anti-DKK1 antibody comprises a heavy chain variable region comprising HCDR1 to HCDR3 and a light chain variable region comprising LCDR1 to LCDR3, wherein the amino acid sequence of HCDR1 is selected from SEQ ID NO: 1, etc., the amino acid sequence of HCDR2 is selected from SEQ ID NO: 2, etc., the amino acid sequence of HCDR3 is selected from SEQ ID NO: 3, etc., the amino acid sequence of LCDR1 is selected from SEQ ID NO: 4, etc., the amino acid sequence of LCDR2 is selected from SEQ ID NO: 5, etc., and the amino acid sequence of LCDR3 is selected from SEQ ID NO: 6, etc.

Abstract: A bifunctional nucleoside hydrogel is formed by dissolving isoguanosine, guanosine and a borate in water or an aqueous solution and then crosslinking same. The bifunctional nucleoside hydrogel integrates a carrier and a drug effect and has a significant inhibitory effect on the activity of tumor cells, and in particular has a significant inhibitory effect on the activity of cells related to lung cancer, glioma, osteoma, colon cancer, breast cancer, oral squamous cell carcinoma and tongue squamous cell carcinoma, of which the inhibitory effect on the activity of cells related to oral squamous cell carcinoma is the best. Therefore, the bifunctional nucleoside hydrogel has potential application prospects in preparing anti-tumor drugs, and particularly, same can provide a new approach for treating oral squamous cell carcinoma.

Abstract: The present disclosure relates, according to some embodiments, to photostable photoactive compositions comprising (a) at least one photoactive compound that develops within itself an excited state energy when subjected to UV radiation and (b) a block copolymer comprising a plurality of blocks, wherein the block copolymer is operable to quench the excited state energy.

Abstract: The present disclosure relates to a method of an anti-PD-1 antibody in combination with chemotherapy in treating esophageal cancer. In particular, the present disclosure relates to a method of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and a chemotherapeutic agent in the preparation of a medicament for treating esophageal cancer. The present disclosure also relates to related drug combination and kit. The present disclosure also relates to a method of a reagent for detecting a gene amplification of chromosome 11q13 region in a test kit for predicting the therapeutic effect of the anti-PD-1 antibody and/or the antigen-binding fragment thereof on an esophageal cancer patient.

Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. Also provided are a nucleic acid molecule encoding the antibody or the functional fragment thereof disclosed herein, an expression vector and a host cell for expressing the antibody or the functional fragment thereof disclosed herein, and a method for preparing the antibody or the functional fragment thereof disclosed herein. The present invention also provides a pharmaceutical composition comprising the antibody or the functional fragment thereof disclosed herein, and use of the antibody or the functional fragment thereof disclosed herein for treating an immune dysfunction disease.

Abstract: The present disclosure relates, according to some embodiments, to photostable photoactive compositions comprising (a) at least one photoactive compound that develops within itself an excited state energy when subjected to UV radiation and (b) a block copolymer comprising a plurality of blocks, wherein the block copolymer is operable to quench the excited state energy.

Abstract: The present disclosure provides a stable anti-PD-1 antibody pharmaceutical composition and use thereof. The pharmaceutical composition includes a buffer and an anti-PD-1 antibody or an antigen-binding fragment thereof; and the anti-PD-1 antibody or the antigen-binding fragment thereof has a concentration of about 100-250 mg/mL, and includes an LCDR1, an LCDR2 and an LCDR3 having amino acid sequences set forth in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and an HCDR1, an HCDR2 and an HCDR3 having amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and and the pharmaceutical composition has a pH of about 5.0-6.5. The present disclosure also provides an injection including the pharmaceutical composition and use of the pharmaceutical composition and the injection in preparing a medicament for treating a disease or disorder by eliminating, inhibiting or reducing PD-1 activity.

Abstract: The present invention relates to an anti-BTLA antibody or an antigen-binding fragment thereof comprising: at least one light chain CDR domain selected from SEQ ID NOs: 7, 8, 9, 10, 11, 12, 16, 17, 18, 22, 23, 24, 31, 32 and 33, and/or at least one heavy chain CDR domain selected from SEQ ID NOs: 1, 2, 3, 4, 5, 6, 13, 14, 15, 19, 20, 21, 25, 26, 27, 28, 29 and 30. The present invention also relates to a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a corresponding expression vector and a host cell, as well as therapeutic use of the antibody or the antigen-binding fragment thereof, the nucleic acid molecule, the expression vector and the host cell.

Abstract: An antibody specifically binding to CD112R or an antigen binding fragment thereof, a composition comprising same, a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen binding fragment thereof, a treatment and diagnostic method using the antibody or the antigen binding fragment thereof, and use of the antibody or the antigen binding fragment thereof.

Abstract: A pod performance test system for a near space aerostat includes: a HCI test control device, a motion simulation control device, a suspension device, and a motion simulation anti-twisting mechanism. The HCI test control device is electronically connected to the motion simulation control device, the motion simulation anti-twisting mechanism and a pod of the near space aerostat separately. The motion simulation control device is electronically connected to the motion simulation anti-twisting mechanism. The motion simulation anti-twisting mechanism is connected to the pod by a connector. The motion simulation control device controls the motion simulation anti-twisting mechanism to simulate various complex motion states according to a motion control parameter from the HCI test control device, and thus the pod is in the various complex motion states. When the pod is in the various complex motion states, performance test results of the pod under the various complex motion states can be obtained.

Abstract: The present invention discloses a method of treating a patient suffering from locally advanced or metastatic urothelial carcinoma, comprising determining a tumor mutational burden of the patient; identifying a candidate exhibiting a high tumor mutational burden, wherein the high tumor mutational burden is ?10 mutations/Mbp; and administering to the candidate a therapeutically effective amount of toripalimab. The present invention also discloses a method of identifying a candidate having mutations in one or more of the following genes occurred in tumor cells: SMARCA4 and RB1.

Abstract: This application provides a method and an apparatus for detecting an electric charging gun mounting status. In the technical solutions provided in this application, a charging device obtains a first voltage value at a first connection confirmation detection point and a second voltage value at a second connection confirmation detection point in a control and guiding circuit of a first charging gun, and obtains a third voltage value at a first connection confirmation detection point and a fourth voltage value at a second connection confirmation detection point in a control and guiding circuit of a first charging socket; and then determines an electric charging gun mounting status of the first charging gun and an electric charging gun mounting status of the first charging socket based on the first voltage value, the second voltage value, the third voltage value, and the fourth voltage value.

Abstract: The present disclosure relates to a method of an anti-PD-1 antibody in combination with first-line chemotherapy in the treatment of advanced non-small cell lung cancer. Specifically, the present disclosure relates to use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and a first-line chemotherapeutic agent in the preparation of a drug for treating non-small cell lung cancer (NSCLC). The present disclosure also relates to a related drug combination and a kit.

Abstract: Some embodiments include a system, method, and non-transitory medium, with the system including an interface to at least one database product; a stateless ping operator to manage lifecycle events associated with the at least one database product; and a first product-specific ping agent to determine an availability of and generate metrics associated with a plurality of instances of a first specific database product of the at least one database product monitored by the first product-specific ping agent, the first product-specific ping agent receiving an assignment of the plurality of instances of the first specific database product to monitor from the ping operator.

Abstract: A system for measurements and calculations of a microcirculatory high-velocity blood flow includes a data acquisition module configured to select and acquire microcirculatory blood vessel image data; a storage module configured to store the acquired microcirculatory blood vessel image data; a velocity measurement module configured to measure a traveling distance and a traveling time of red blood cell (RBC), white blood cell (WBC), or plasma particles in a blood vessel sample and calculate a ratio of the traveling distance to the traveling time to obtain a blood flow velocity; and a high-velocity blood flow index module configured to determine an index level for the microcirculatory high-velocity blood flow. Specifically, an initial threshold, i.e. 1000 ?m/s, for the microcirculatory high-velocity blood flow of sepsis is proposed, which facilitates early diagnosis on sepsis. The changing process of the high-velocity blood flow shows development of the early-stage, intermediate-stage and end-stage sepsis.

Abstract: A digital mirroring method includes creating a digital model for each physical device of a plurality of physical devices located in a physical space. Once a related data of each physical device is obtained, the related data of each physical device is mapped to corresponding digital model.

Abstract: This application provides a charging plug and socket-outlet, charging and to-be-charged apparatuses, a charging system, and a control method. The charging system includes: a charging apparatus and a to-be-charged apparatus. The charging apparatus includes a charging plug and a first cooling system. The charging plug includes a first electrical transmission interface, a first heat conduction output interface, and a first heat conduction input interface. The to-be-charged apparatus includes a battery, a charging socket-outlet, and a second cooling system. The charging socket-outlet includes a second electrical transmission interface, a second heat conduction output interface, and a second heat conduction input interface. The solutions of this application can be used to meet a heat dissipation requirement of the battery in the to-be-charged apparatus during super charging.

Abstract: The present disclosure provides a bispecific antibody including a binding domain that binds to CD112R and a binding domain that binds to TIGIT, and the binding domain that binds to CD112R includes: HCDR1, HCDR2 and HCDR3 of the amino acid sequence set forth in SEQ ID NO: 1, and/or LCDR1, LCDR2 and LCDR3 of the amino acid sequence set forth in SEQ ID NO: 2; and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. The present disclosure further provides a polynucleotide encoding the antibody, an expression vector, a host cell and a method for expressing and purifying the antibody, a pharmaceutical composition including the antibody of the present disclosure, and use of the bispecific antibody for treating cancer.

Abstract: A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition includes a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.